MXPA03009850A - Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso. - Google Patents

Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.

Info

Publication number
MXPA03009850A
MXPA03009850A MXPA03009850A MXPA03009850A MXPA03009850A MX PA03009850 A MXPA03009850 A MX PA03009850A MX PA03009850 A MXPA03009850 A MX PA03009850A MX PA03009850 A MXPA03009850 A MX PA03009850A MX PA03009850 A MXPA03009850 A MX PA03009850A
Authority
MX
Mexico
Prior art keywords
bisarylimidazolyl
fatty acid
acid amide
amide hydrolase
hydrolase inhibitors
Prior art date
Application number
MXPA03009850A
Other languages
English (en)
Inventor
Sit Sing-Yuen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03009850A publication Critical patent/MXPA03009850A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA03009850A 2001-04-27 2002-04-23 Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso. MXPA03009850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28682701P 2001-04-27 2001-04-27
PCT/US2002/012853 WO2002087569A1 (en) 2001-04-27 2002-04-23 Bisarylimidazolyl fatty acid amide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03009850A true MXPA03009850A (es) 2004-02-12

Family

ID=23100337

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009850A MXPA03009850A (es) 2001-04-27 2002-04-23 Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.

Country Status (7)

Country Link
US (2) US6562846B2 (es)
EP (1) EP1389107A4 (es)
JP (1) JP2004532229A (es)
CA (1) CA2445294A1 (es)
IL (1) IL158300A0 (es)
MX (1) MXPA03009850A (es)
WO (1) WO2002087569A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU2003210824A1 (en) * 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
MXPA05003715A (es) * 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
US20080103209A1 (en) * 2004-04-23 2008-05-01 The Regents Of The University Of California Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
WO2006044617A1 (en) 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
ME02222B (me) 2004-12-30 2016-02-20 Janssen Pharmaceutica Nv Amid derivati piperidin-i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za liječenje tjeskobe, boli i drugih stanja
CN101247853B (zh) * 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
AU2007217813A1 (en) 2006-02-17 2007-08-30 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
KR100753240B1 (ko) 2006-03-10 2007-08-30 한국지질자원연구원 합금 나노분말의 제조방법
EP2708262A3 (en) 2007-10-12 2014-04-23 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Therapeutic applications of fatty acid amide hydrolase inhibitors
EP2062578A1 (en) * 2007-11-12 2009-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel use of chemical compounds for the treatment of AIDS
NZ586082A (en) 2007-11-16 2013-03-28 Neuraxon Inc Indole compounds and methods for treating visceral pain
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
WO2011030798A1 (ja) 2009-09-09 2011-03-17 大日本住友製薬株式会社 ８－オキソジヒドロプリン誘導体
US20120225097A1 (en) 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
US9737562B2 (en) 2012-12-11 2017-08-22 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
CN111269083B (zh) * 2020-02-24 2023-08-25 珠海市柏瑞医药科技有限公司 一种格尔伯特酸的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT91878B (pt) * 1988-10-03 1995-05-31 Glaxo Group Ltd Processo para a preparacao de derivados do imidazole com propriedades hipocolesterolemicas e hipolipidemicas
WO1993016674A1 (en) * 1992-02-11 1993-09-02 Smithkline Beecham Corporation CoA-IT AND PAF INHIBITORS
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance

Also Published As

Publication number Publication date
IL158300A0 (en) 2004-05-12
US6562846B2 (en) 2003-05-13
JP2004532229A (ja) 2004-10-21
US20020188009A1 (en) 2002-12-12
EP1389107A1 (en) 2004-02-18
EP1389107A4 (en) 2005-10-12
USRE39634E1 (en) 2007-05-15
WO2002087569A1 (en) 2002-11-07
CA2445294A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
MXPA03009850A (es) Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
AU2003210824A8 (en) (oxime)carbamoyl fatty acid amide hydrolase inhibitors
GB0125445D0 (en) Protease Inhibitors
HUP0401052A3 (en) Dna-pk inhibitors
EP1569633A4 (en) CA-IX SPECIFIC HEMMER
AU2001270200A1 (en) Fatty acid synthase inhibitors
AU2001281059A1 (en) Fatty acid synthase inhibitors
GB0018164D0 (en) Corrosion inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU2001271531A1 (en) Fatty acid synthase inhibitors
MXPA03009091A (es) Amidas novedosas del acido n-p-propargiloxifenetil-tioacetico.
GB2359500B (en) Corrosion inhibitors
EP1401453A4 (en) PROTEASE INHIBITORS
AU2002243439A1 (en) Fatty acid synthase inhibitors
AU2001274940A1 (en) Fatty acid synthase inhibitors
HK1075885A1 (en) 20-Hydroxyeicosatetraenoic acid production inhibitors
EP1364653A4 (en) CASOASE-3 INHIBITORS
AU2001271718A1 (en) Fatty acid synthase inhibitors
EP1428876A4 (en) NEW AMIDE HYDROLASE GENE
GB0109278D0 (en) Enzyme inhibitors
EP1318806A4 (en) INHIBITORS OF FATTY ACID SYNTASES
AU2001284705A1 (en) Fatty acid synthase inhibitors
GB0102018D0 (en) Enzyme inhibitors
GB0106564D0 (en) Enzyme inhibitors

Legal Events

Date Code Title Description
FG Grant or registration